Update on obinutuzumab in the treatment of B-cell malignancies.
| dc.contributor.author | Illidge, Timothy M | |
| dc.contributor.author | Cheadle, Eleanor J | |
| dc.contributor.author | Donaghy, Clare | |
| dc.contributor.author | Honeychurch, Jamie | |
| dc.date.accessioned | 2014-10-08T10:08:00Z | |
| dc.date.available | 2014-10-08T10:08:00Z | |
| dc.date.issued | 2014-10 | |
| dc.identifier.citation | Update on obinutuzumab in the treatment of B-cell malignancies. 2014, 14 (10):1507-17 Expert Opin Biol Ther | en |
| dc.identifier.issn | 1744-7682 | |
| dc.identifier.pmid | 25190612 | |
| dc.identifier.doi | 10.1517/14712598.2014.948414 | |
| dc.identifier.uri | http://hdl.handle.net/10541/332335 | |
| dc.description.abstract | The anti-CD20 mAb rituximab has revolutionized the treatment of B-cell malignancies, improving outcome for patients. Despite these improvements, the majority of patients still relapse and become refractory to rituximab. Further efforts to improve anti-CD20 mAb efficacy have recently focused on obinutuzumab /GA101, a novel anti-CD20 mAb glycoengineered to display enhanced Fc-mediated effector mechanisms and induce direct cell death. | |
| dc.language.iso | en | en |
| dc.rights | Archived with thanks to Expert opinion on biological therapy | en |
| dc.title | Update on obinutuzumab in the treatment of B-cell malignancies. | en |
| dc.type | Article | en |
| dc.contributor.department | University of Manchester, Institute of Cancer Sciences, The Christie Hospital, Manchester Cancer Research Centre, Manchester Academic Health Sciences Centre , Manchester M20 4BX , UK +44 0 161 446 8110 ; +44 0 161 446 8001 ; tmi@manchester.ac.uk. | en |
| dc.identifier.journal | Expert Opinion on Biological Therapy | en |
| dc.description.collection | Lymphoma Research Team | en |
| html.description.abstract | The anti-CD20 mAb rituximab has revolutionized the treatment of B-cell malignancies, improving outcome for patients. Despite these improvements, the majority of patients still relapse and become refractory to rituximab. Further efforts to improve anti-CD20 mAb efficacy have recently focused on obinutuzumab /GA101, a novel anti-CD20 mAb glycoengineered to display enhanced Fc-mediated effector mechanisms and induce direct cell death. |